Showing results (81-90 of 109) with videos related to
Sort By:
Pageof 11
Blood|September 20, 2002
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trialHervé Dombret, Jean Gabert, Jean-Michel Boiron, et al.Blood Cancer Journal|January 27, 2022
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteinsThomas Steimlé, Marie-Emilie Dourthe, Marion Alcantara, et al.Leukemia Research|May 21, 2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMCHyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, et al.Cancer|May 4, 2018
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study GroupDelphine Rea, Shanti Ame, Marc Berger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association GroupMarie Balsat, Aline Renneville, Xavier Thomas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable diseasePhilippe Rousselot, Aude Charbonnier, Pascale Cony-Makhoul, et al.Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.British Journal of Haematology|December 20, 2014
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to reactCécile Pochon, Emmanuel Oger, Gérard Michel, et al.British Journal of Haematology|July 1, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patientsPhilippe Rousselot, Luigina Mollica, Joëlle Guilhot, et al.Blood|April 18, 2014
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemiaKheira Beldjord, Sylvie Chevret, Vahid Asnafi, et al.Pageof 11